S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
AURA · Aura Biosciences, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Aura Biosciences Inc (AURA)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$6.45
-0.10
(-1.60%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$6.45
$6.38
$6.61
52-WEEK RANGE
$6.45
$4.73
$9.54
What's happening
- AURA is down 1.60% today, trading at $6.45. — Live quote
- Volume today (90,037) is well below its 3-month average of 775,500. (Finnhub fundamentals)
- Reports earnings on 2026-11-05 (before market open), 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.48 actual vs. $-0.38 estimated (-25.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
AURA
+18.53%
vs S&P 500
+5.16%
1-YEAR RETURN
AURA
+5.56%
vs S&P 500
-9.61%
6-MONTH RETURN
AURA
-11.39%
3-MONTH RETURN
AURA
-7.85%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.48
Est. $-0.38
MISS -25.8%
2026-04-26 (Q1 2026)
$-0.50
Est. $-0.41
MISS -23.3%
2026-01-26 (Q4 2025)
$-0.37
Est. $-0.44
BEAT +15.2%
2025-10-26 (Q3 2025)
$-0.40
Est. $-0.48
BEAT +15.9%
Valuation Measures & Ratios
Enterprise Value4$602.1M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book72.33
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-73.18%
Return on Assets (ROA9)-62.00%
Avg Volume (3M)775,500
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $676.0M | $450.7M | $403.7M | $360.2M | $294.3M |
| P/E | -5.10 | -3.94 | -3.97 | -3.76 | -3.32 |
| Price/Book | 2.14 | 4.20 | 2.58 | 2.06 | 2.30 |
| ROE | -42.02% | -106.59% | -64.90% | -54.91% | -69.21% |
| ROA | -38.05% | -83.03% | -53.51% | -46.91% | -56.99% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short10,366,122
Change from Prior Settlement+47.04%
% of Float—
Days to Cover (Short Ratio)9.23
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +5.6%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-09-01; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on AURA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$48.1M | -$34.9M | -$27.9M | -$28.6M | -$29.0M | -$23.2M | -$22.8M | -$22.3M |
| Net income | -$45.6M | -$33.7M | -$26.1M | -$27.0M | -$27.5M | -$21.0M | -$20.3M | -$19.7M |
| EPS (diluted) | $-0.48 | $-0.50 | $-0.40 | $-0.47 | $-0.55 | $-0.42 | $-0.41 | $-0.40 |
| EPS (basic) | $-0.48 | $-0.50 | $-0.40 | $-0.47 | $-0.55 | $-0.42 | $-0.41 | $-0.40 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $348.1M | $137.7M | $169.4M | $190.0M | $204.4M | $155.4M | $182.5M | $205.3M |
| Total liabilities | $32.9M | $30.4M | $32.5M | $33.4M | $29.8M | $27.4M | $30.5M | $30.7M |
| Stockholders' equity | $315.3M | $107.2M | $136.9M | $156.7M | $174.6M | $128.0M | $152.0M | $174.7M |
| Total current assets | $329.0M | $118.5M | $149.7M | $170.1M | $184.0M | $134.5M | $160.6M | $183.5M |
| Total current liabilities | $19.6M | $16.7M | $18.4M | $18.8M | $14.9M | $12.2M | $14.9M | $14.7M |
| Cash & equivalents | $67.8M | $84.8M | $59.5M | $47.6M | $107.4M | $38.2M | $31.7M | $25.4M |
| Other current assets | $819.0K | $1.1M | $660.0K | $2.6M | $2.6M | $1.8M | $1.8M | $3.4M |
| Property, plant & equipment | $2.2M | $2.5M | $2.6M | $2.6M | $2.9M | $3.1M | $3.2M | $3.3M |
| Other non-current assets | $1.1M | $517.0K | $471.0K | $277.0K | $185.0K | $0 | $518.0K | $22.0K |
| Accounts payable | $2.3M | $2.6M | $1.5M | $1.9M | $1.3M | $2.0M | $2.3M | $2.0M |
| Common stock & paid-in capital | $1.0K | — | — | — | — | — | — | — |
| Retained earnings | -$559.7M | -$514.1M | -$480.4M | -$454.9M | -$428.7M | -$401.7M | -$374.2M | -$348.4M |
| Accumulated other comprehensive income (loss) | -$670.0K | -$207.0K | -$102.0K | $69.0K | $25.0K | $105.0K | $263.0K | $607.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.5M | -$29.9M | -$20.5M | -$20.1M | -$20.8M | -$23.4M | -$24.0M | -$15.3M |
| Investing cash flow | -$226.0M | $54.9M | $29.8M | -$44.0M | $20.0M | $29.8M | $29.7M | $9.9M |
| Financing cash flow | $241.8M | $300.0K | $2.8M | $4.4M | $69.9M | $96.0K | $543.0K | $716.0K |
| Free cash flow | -$32.5M | -$30.0M | -$20.6M | -$20.2M | -$20.8M | -$23.5M | -$24.3M | -$15.6M |
| Capital expenditures | $21.0K | $102.0K | $176.0K | $45.0K | $39.0K | $187.0K | $299.0K | $341.0K |
| Share-based compensation | $12.4M | $3.8M | $3.3M | $3.7M | $3.8M | $3.5M | $2.9M | $2.8M |
| Change in accounts payable | -$326.0K | $1.0M | -$430.0K | $602.0K | -$720.0K | -$298.0K | $310.0K | $689.0K |
| Purchases of investments | $256.0M | — | $0 | $74.0M | $10.0M | $0 | $0 | $20.0M |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
| Share repurchases | $39.1M | — | — | — | $0 | — | — | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$112.8M | -$96.1M | -$85.0M | -$60.3M | -$35.2M |
| Net income | -$106.2M | -$86.9M | -$76.4M | -$58.8M | -$35.3M |
| EPS (diluted) | $-1.76 | $-1.75 | $-1.93 | $-1.96 | $-8.95 |
| EPS (basic) | $-1.76 | $-1.75 | $-1.93 | $-1.96 | $-8.95 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $169.4M | $182.5M | $255.1M | $223.9M | $160.0M |
| Total liabilities | $32.5M | $30.5M | $29.2M | $28.4M | $7.7M |
| Stockholders' equity | $136.9M | $152.0M | $225.8M | $195.6M | $152.3M |
| Total current assets | $149.7M | $160.6M | $231.8M | $196.7M | $153.7M |
| Total current liabilities | $18.4M | $14.9M | $12.4M | $10.5M | $7.4M |
| Cash & equivalents | $59.5M | $31.7M | $41.1M | $121.6M | $149.1M |
| Other current assets | $1.2M | $1.8M | $2.4M | $715.0K | $66.0K |
| Property, plant & equipment | $2.6M | $3.2M | $3.1M | $5.4M | $5.3M |
| Other non-current assets | $471.0K | $518.0K | $509.0K | $423.0K | — |
| Accounts payable | $1.5M | $2.3M | $1.8M | $2.9M | $2.4M |
| Retained earnings | -$480.4M | -$374.2M | -$287.3M | -$210.9M | -$152.1M |
| Accumulated other comprehensive income (loss) | -$102.0K | $263.0K | $539.0K | -$72.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$84.7M | -$79.8M | -$63.8M | -$54.6M | -$32.4M |
| Investing cash flow | $35.6M | $68.8M | -$114.0M | -$67.9M | -$2.1M |
| Financing cash flow | $77.2M | $1.6M | $97.3M | $95.6M | $166.3M |
| Free cash flow | -$85.2M | -$81.1M | -$64.6M | -$55.7M | -$34.5M |
| Capital expenditures | $447.0K | $1.3M | $709.0K | $1.1M | $2.1M |
| Share-based compensation | $14.3M | $11.7M | $8.8M | $6.4M | $2.3M |
| Change in accounts payable | -$846.0K | $482.0K | -$1.0M | $340.0K | $1.1M |
| Purchases of investments | $84.0M | $59.1M | $233.7M | $119.8M | — |
| Other financing activities | — | — | — | — | -$15.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding AURA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-17 to 2026-09-01
Recent transactions
- Insiders have net sold 6,935,694 shares over the last 182 days, across 0 purchases and 2 sales.
- Most recent: Person Julie (Chief People Officer) — Grant / award of 107,611 shares on 2026-09-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)6,935,694 sh(2 txns)
Net Shares-6,935,694
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Person Julie | Chief People Officer | Grant / award | 2026-09-01 | 107,611 |
| Kratz Erica | Chief Reg. & Quality Officer | Grant / award | 2026-09-01 | 100,885 |
| Hopkins Janet Jill | Chief Medical Officer | Grant / award | 2026-09-01 | 58,850 |
| Elazzouzi Amy | SVP, Finance & PAO | Grant / award | 2026-09-01 | 23,540 |
| Abu-Absi Susan | Chief Operating Officer | Grant / award | 2026-09-01 | 134,513 |
| Bender Jeremy | Reporting person | Grant / award | 2026-07-07 | 30,000 |
| Kilroy Conor | See Remarks | Grant / award | 2026-07-01 | 14,858 |
| Gibney Anthony S | See Remarks | Open market sale | 2026-06-16 | 12,824 |
| Bitetti Teresa Marie | Reporting person | Grant / award | 2026-06-11 | 15,000 |
| Srivastava Sapna | Reporting person | Grant / award | 2026-06-11 | 15,000 |
| Johnson David Michael | Reporting person | Grant / award | 2026-06-11 | 15,000 |
| Mattessich Antony C. | Reporting person | Grant / award | 2026-06-11 | 15,000 |
| Holles Natalie C. | See Remarks | Grant / award | 2026-05-19 | 600,118 |
| Matrix Capital Management Company, LP | 10% owner | Open market sale | 2026-05-07 | 6,922,870 |
| de los Pinos Elisabet | See Remarks | Grant / award | 2026-03-02 | 166,000 |
| Plavsic Mark | Chief Technology Officer | Grant / award | 2026-03-02 | 62,339 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-01 | Person Julie | Chief People Officer | Grant / award | 107,611 | $0.00 |
| 2026-09-01 | Kratz Erica | Chief Reg. & Quality Officer | Grant / award | 100,885 | $0.00 |
| 2026-09-01 | Hopkins Janet Jill | Chief Medical Officer | Grant / award | 58,850 | $0.00 |
| 2026-09-01 | Elazzouzi Amy | SVP, Finance & PAO | Grant / award | 23,540 | $0.00 |
| 2026-09-01 | Abu-Absi Susan | Chief Operating Officer | Grant / award | 134,513 | $0.00 |
| 2026-07-07 | Bender Jeremy | Reporting person | Grant / award | 30,000 | $0.00 |
| 2026-07-01 | Kilroy Conor | See Remarks | Grant / award | 14,858 | $0.00 |
| 2026-06-16 | Gibney Anthony S | See Remarks | Open market sale | 12,824 | $6.42 |
| 2026-06-11 | Bitetti Teresa Marie | Reporting person | Grant / award | 15,000 | $0.00 |
| 2026-06-11 | Srivastava Sapna | Reporting person | Grant / award | 15,000 | $0.00 |
| 2026-06-11 | Johnson David Michael | Reporting person | Grant / award | 15,000 | $0.00 |
| 2026-06-11 | Mattessich Antony C. | Reporting person | Grant / award | 15,000 | $0.00 |
| 2026-05-19 | Holles Natalie C. | See Remarks | Grant / award | 600,118 | $0.00 |
| 2026-05-19 | Holles Natalie C. | See Remarks | Grant / award | 553,844 | $0.00 |
| 2026-05-07 | Matrix Capital Management Company, LP | 10% owner | Open market sale | 6,922,870 | $5.64 |
| 2026-04-16 | Kilroy Conor | See Remarks | Open market sale | 11,738 | $7.02 |
| 2026-03-02 | Kilroy Conor | See Remarks | Grant / award | 62,339 | $0.00 |
| 2026-03-02 | Gibney Anthony S | See Remarks | Grant / award | 71,245 | $0.00 |
| 2026-03-02 | de los Pinos Elisabet | See Remarks | Grant / award | 166,000 | $0.00 |
| 2026-03-02 | Plavsic Mark | Chief Technology Officer | Grant / award | 62,339 | $0.00 |
| 2026-03-02 | Hopkins Janet Jill | Chief Medical Officer | Grant / award | 89,056 | $0.00 |
| 2026-03-02 | Elazzouzi Amy | Senior Vice President, Finance | Grant / award | 44,528 | $0.00 |
| 2026-02-17 | Kilroy Conor | See Remarks | Open market sale | 12,079 | $5.05 |
| 2026-02-17 | Plavsic Mark | Chief Technology Officer | Open market sale | 15,890 | $5.05 |
| 2026-02-17 | Hopkins Janet Jill | Chief Medical Officer | Open market sale | 20,401 | $5.06 |
| 2026-02-17 | Elazzouzi Amy | Senior Vice President, Finance | Open market sale | 8,549 | $5.06 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:06 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-01 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-07 | View on SEC.gov → |
| 2026-07-08 | 8-K | 2026-07-03 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-06-16 | 4 | 2026-06-16 | View on SEC.gov → |
Recent news
Headlines about AURA (Aura Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
XGIMI's AURA 3 Series Achieves Record-Breaking Kickstarter Launch, Hits $10M in 2 Hours and Surpasses $15M in 23 Hours
Yahoo Finance · 2026-10-21 -
Lava Aura Curve 5G Launched in India: 7 Key Features
thedigitalbriefnews.com · 2026-10-21 -
Lava Aura Curve 5G launched in India at Rs 23,999 with curved AMOLED display, 6,000mAh battery
Business Today · 2026-10-21 -
Lava Aura Curve Launched in India at Rs 23,999, Check Specs
NewsBricks · 2026-10-21 -
Lava Aura Curve Launched In India With Mini Rear Display, 6,000mAh Battery At Rs 23,999
NDTV Profit · 2026-10-21 -
Lava Aura Curve 5G launched in India at Rs 23,999: Features and specifications
Moneycontrol.com · 2026-10-21 -
Lava Aura Curve Specs and Price: The Offline Twin to the Virat Curve
Nokiamob · 2026-10-21 -
Lava Aura Curve Launched in India With Mini Rear Display, 6,000mAh Battery: Price, Features
Gadgets 360 · 2026-10-21
No headlines in this category right now — try “All”.